SMSaba Molhemi

Saba Molhemi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saba Molhemi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Isoflurane anesthesia alters 31P magnetic resonance spectroscopy markers compared to awake mouse brain

    by Saba Molhemi, Rasmus West Knopper, Christian Stald Skoven, Thomas Beck Lindhardt, Caroline Degel, Leif Østergaard, Brian Hansen

    Normal brain function hinges on energy-intensive processes. Consequently, alterations to the brain’s metabolic state are common hallmarks in several pathological conditions. Phosphorus Magnetic Resonance Spectroscopy ( 31 P MRS) is a noninvasive method for measuring key markers of brain energy metabolism, including adenosine triphosphate (ATP), inorganic phosphate (Pi), and phosphocreatine (PCr), as well as markers for cell membrane phospholipid turnover, phosphomonoester (PME) and phosphodiester (PDE). Preclinical rodent 31 P MRS has so far been done under anesthesia - with isoflurane being one of the most commonly used anesthetic agents. The use of isoflurane in 31 P MRS is a concern, as anesthetics are known to affect neuronal activity and energy metabolism in the brain. Its use therefore comes with a risk of perturbing brain physiology. Awake mouse MRS avoids this and allows the effect of isoflurane to be quantified. Thus, we here compare mouse brain 31 P MRS in awake MR-habituated mice and isoflurane anesthesia. We find that 31 P metabolite levels differ between the awake state and isoflurane anesthesia in mice. Our findings show that low-dose isoflurane anesthesia reduces PCr levels in the mouse brain and is accompanied by decreases in intracellular pH and decreased PME levels.


  • Open Access

    Comprehensive Analysis of the 5xFAD Mouse Model of Alzheimer’s Disease Using dMRI, Immunohistochemistry, and Neuronal and Glial Functional Metabolic Mapping

    by Emil W. Westi, Saba Molhemi, Caroline Termøhlen Hansen, Christian Stald Skoven, Rasmus West Knopper, Dashne Amein Ahmad, Maja B. Rindshøj, Aishat O. Ameen, Brian Hansen, Kristi A. Kohlmeier, et al.

    Alzheimer’s disease (AD) is characterized by complex interactions between neuropathological markers, metabolic dysregulation, and structural brain changes. In this study, we utilized a multimodal approach, combining immunohistochemistry, functional metabolic mapping, and microstructure sensitive diffusion MRI (dMRI) to progressively investigate these interactions in the 5xFAD mouse model of AD. Our analysis revealed age-dependent and region-specific accumulation of key AD markers, including amyloid-beta (Aβ), GFAP, and IBA1, with significant differences observed between the hippocampal formation and upper and lower regions of the cortex by 6 months of age. Functional metabolic mapping validated localized disruptions in energy metabolism, with glucose hypometabolism in the hippocampus and impaired astrocytic metabolism in the cortex. Notably, increased cortical glutaminolysis suggested a shift in microglial metabolism, reflecting an adaptive response to neuroinflammatory processes. While dMRI showed no significant microstructural differences between 5xFAD and wild-type controls, the study highlights the importance of metabolic alterations as critical events in AD pathology. These findings emphasize the need for targeted therapeutic strategies addressing specific metabolic disturbances and underscore the potential of integrating advanced imaging with metabolic and molecular analyses to advance our understanding of AD progression.